Study Links Vaping to Irregular Heartbeats in Mice

Nov.03.2022
Study Links Vaping to Irregular Heartbeats in Mice
A study on e-cigarette liquids causing heart rhythm disruption in mice is criticized for its lack of relevance to humans.

A newspaper has reported on a study claiming that electronic cigarette liquid can disrupt heart rhythms, but has failed to highlight that the study was conducted on mice and involved toxic doses. An expert on tobacco reduction has pointed out that the only information this study provides is that "pet mouse owners should not allow their mice to use electronic cigarettes.


According to The Independent, a new study has found that using e-cigarette fluids containing certain ingredients can cause heart rhythm irregularities, thereby increasing the risk of heart attacks.


A recent study published in Nature Communications suggests that e-cigarettes and their individual components can cause irregular heart rhythms and conduction defects in mice. The researchers conducted electrocardiogram tests on mice after acute inhalation of e-cigarette vapors. They argue that "our findings suggest that the chemical composition of e-cigarettes may increase cardiac risk by inducing changes that promote arrhythmogenesis and stimulate autonomic reflexes.


Experts in tobacco harm reduction and e-cigarettes quickly criticized the study. Professor Jacob George, Head of Cardiovascular Medicine and Therapeutics at the University of Dundee Medical School, said: "The metabolism of mice is very different from that of humans, and to be honest, any inference to long-term human health effects are at best speculative. If this were indeed true, given the large number of e-cigarette users worldwide, we would have expected to see a dramatic increase in cases of arrhythmia, which we have not seen in clinical practice.


The controversial nature of e-cigarettes brings into question the preliminary and speculative science surrounding its potential impact on human health, including the effects of nicotine on blood vessels. However, large-scale observational studies of users of nicotine replacement therapy have shown no increase in heart events. These findings should not deter those seeking to quit smoking from attempting e-cigarettes or nicotine replacement therapy. This early-stage preclinical research requires further clinical work before it can be considered directly related to human health.


Professor Peter Hajek, director of the Tobacco Dependence Research Department at Queen Mary University of London, added that "in this study, mice were exposed to aerosols from e-cigarette solvents with and without nicotine, as well as acrolein (a chemical that may be produced due to overheating) in e-cigarette liquid. Such exposure was associated with short-term changes in the mice's electrocardiograms and an increase in heart rate.


When talking about applying the results of this study to humans, there are several issues to consider. Electronic cigarette users are unlikely to be exposed to significant levels of acrolein since overheated e-liquid produces an unpleasant taste that people tend to avoid. While the study used exposure levels to other chemicals that humans can tolerate, the same dose may cause significant pain in much smaller mammals with more sensitive olfactory systems and varying tolerances to medication. It would be strange if animals exposed to aversive stimuli did not show a cardiovascular response. The reason for using mice in this study remains unclear. When experiments cannot be conducted on humans, animal models may be used, but comparing heart rate and electrocardiograms for electronic cigarette components and human smoking reactions is not without hurdles.


Professor Kevin McConway, Honorary Professor of Applied Statistics at The Open University in the UK, continues to criticize and has released a detailed statement saying: "As a statistician and not a biologist, I am unable to comment on the physiological details of this study. However, in my view, most aspects of the statistical analysis of the experimental results are reliable, and the study provides good evidence that certain components of e-cigarettes do indeed affect some aspects of mouse heart function when the mice are exposed to these components in the way done in this study. Nevertheless, while I believe that investigating the potential harmful effects of e-cigarette components is certainly worthwhile, and I also believe that animal experiments can play a role in this work, this work cannot answer some important questions.


I don't believe any knowledgeable commentator has suggested that using e-cigarettes is without risk. The important question is how the harm of using e-cigarettes compares to the harm that would result if the person did not use them. This, of course, depends on what the person would do if they did not use e-cigarettes. If they are a traditional smoker and e-cigarettes help them quit, then using e-cigarettes would prevent greater harm from their previous smoking habit. Other studies have shown that e-cigarettes can effectively help people quit smoking and are often more effective than nicotine replacement therapy like patches or gum. So, when used by smokers, the real question is not whether e-cigarettes are completely harmless, but whether they are safer than continuing to smoke or using other methods to quit, which may be less effective. This new study does not shed light on that question, and there is no evidence in its findings to suggest that using e-cigarettes is as harmful as smoking regular cigarettes, even in mice.


For those who are not yet smokers, electronic cigarette companies say it may be different. However, people still need to consider whether using electronic cigarettes may lead to other dangerous habits, such as using different drugs.


To the best of my understanding, this study has the potential to distinguish the effects of different components in e-cigarettes to some extent, which is an advantage. For example, this could lead to the development of safer e-cigarettes. However, as noted by the researchers, the reactions to various chemicals observed in mice may not necessarily apply to humans, even though this study specifically looks at several components of e-cigarettes and their potential effects on mice. Therefore, there is still a lot of work to be done and all relevant factors must be taken into consideration.


In addition, the study used a very small number of female mice - only four - and these mice did not come into contact with most of the substances involved. This means that, as the researchers have themselves acknowledged, some of the potential conclusions about gender differences are not based on evidence. Finally, these mice were (of course) completely unfamiliar with e-cigarettes, and the researchers note that the effects may be very different for individuals who have experience with e-cigarettes or tobacco use.


Dr. Adam Jacobs, Senior Director of Biostatistics at Premier Research, provided commentary on the study, stating "This study suggests that mice exposed to e-cigarette aerosol in a closed space for 90 minutes experience short-term changes in heart rhythm. While the long-term effects of these changes are not yet clear, it seems prudent for pet owners to avoid exposing their rodents to e-cigarettes. For humans, while e-cigarettes cannot be considered completely safe, there is a significant amount of evidence showing it to be much safer than smoking combustible cigarettes. Therefore, smokers who switch from traditional cigarettes to e-cigarettes will greatly reduce their health risks.


Statement:


The content of this article is compiled from third-party information and is only intended for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of its content. The translation of this article is only intended for industry communication and research purposes.


Due to limitations in the translator's skills, the translated article may not fully express the same meaning as the original text. Please refer to the original text for accuracy.


2FIRSTS remains completely aligned with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Sweden Threatens EU Tobacco Tax Deal as Nicotine Pouch Duty Dispute Looms Over November 9 Meeting
Sweden Threatens EU Tobacco Tax Deal as Nicotine Pouch Duty Dispute Looms Over November 9 Meeting
Sweden is expected to oppose a European Union proposal to raise minimum tobacco excise duties, Law360 reported on October 26, 2026, citing an EU official. A provisional Council agenda dated October 23 confirms that the tobacco taxation package is scheduled for discussion at the November 9 finance ministers' meeting, where member states will seek a general approach. The proposed reforms would raise minimum taxes on conventional tobacco products and establish EU-wide excise rules for vaping liquids, heated tobacco and nicotine pouches. Sweden supports harmonising tobacco taxation rules but objects to requiring nicotine pouches to bear the same minimum tax burden as certain smoking tobacco products. As EU indirect tax legislation requires unanimous Council approval, Swedish opposition could block the proposal in its current form.
Regulations
Oct.29
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania's Act 57 vape directory regime will reach the end of its 120-day inventory transition period on Oct. 19. Nicotine-containing e-cigarettes intended for retail sale in the state that are not listed on the Attorney General's ENDS directory will then be barred from retail sale and treated as contraband subject to seizure, forfeiture and destruction. Manufacturers face annual product certification, brand- and style-based fees and a minimum $50,000 surety bond, while retailers and wholesalers must source through licensed channels and monitor the directory.
Regulations
Oct.08
Special Report|Virginia Vape Directory Shows Contrast Between Vuse and JUUL Pod Systems and CrossBar 20K, Loon Flavored Disposables
Special Report|Virginia Vape Directory Shows Contrast Between Vuse and JUUL Pod Systems and CrossBar 20K, Loon Flavored Disposables
A 2Firsts analysis of Virginia's liquid nicotine and vapor product certification directory identified 213 product records from 15 manufacturers. Companies associated with BAT, Altria, Imperial Brands, JTI and JUUL account for 127 entries. The directory also includes independent brands CrossBar 20K, Loon and Breeze. CrossBar advertises a 13mL disposable capable of up to 20,000 puffs, while Loon has 16 disposable entries featuring fruit, cooling and beverage-related flavors. Of all records, 120 are labeled as under FDA PMTA review. Virginia introduced revised penalties on October 1, 2026, including a minimum first-violation civil penalty of $5,000 per unlisted product, alongside new retail tobacco permitting requirements.
Regulations
Oct.30
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
Product | JT Launches Three Autumn-Limited Ploom Tobacco Sticks in Japan Across EVO, MEVIUS and CAMEL Brands
Product | JT Launches Three Autumn-Limited Ploom Tobacco Sticks in Japan Across EVO, MEVIUS and CAMEL Brands
Japan Tobacco Inc. (JT) launched three limited-edition autumn tobacco sticks for its Ploom heated tobacco devices in Japan on October 16, 2026, under the EVO, MEVIUS and CAMEL brands. All three are regular tobacco variants with seasonal packaging. Each pack contains 20 sticks, priced at ¥620, ¥590 and ¥570, respectively, including tax. The products are compatible with all Ploom devices and are sold in limited quantities exclusively through the CLUB JT online store while supplies last.
product
Oct.20
Imperial Brands' NGP Revenue Rises 11.4% in FY2026 but Business Still Posts £63 Million Loss; Zone Reaches 114,000 US Stores as Smokeless Reporting Takes Shape
Imperial Brands' NGP Revenue Rises 11.4% in FY2026 but Business Still Posts £63 Million Loss; Zone Reaches 114,000 US Stores as Smokeless Reporting Takes Shape
Imperial Brands reported an 11.4% increase in next-generation product (NGP) net revenue to £419 million in fiscal 2026, while its adjusted NGP operating loss narrowed to £63 million. European NGP revenue rose 16.8%, while the Americas recorded a 17.1% decline. Global modern oral nicotine volumes increased 27.8%, with US nicotine pouch brand Zone expanding to approximately 114,000 stores. The company also acquired Black Buffalo in the US and Helwit in Sweden, broadening its oral nicotine portfolio. From FY2027, Imperial Brands will adopt a new Smokeless reporting category combining NGP with traditional oral tobacco. On the new basis, FY2026 Smokeless net revenue was £554 million, with adjusted operating profit of £14 million.
company
Nov.18